The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis Joe Datt, Laura Baldock, Emily Pull, Bryn Webber Multiple Sclerosis and Related Disorders Volume 5, Pages 40-46 (January 2016) DOI: 10.1016/j.msard.2015.10.009 Copyright © 2015 The Authors Terms and Conditions
Fig. 1 Geographic spread of UK NHS hospital Trusts supported by the RPHC FDO service. Multiple Sclerosis and Related Disorders 2016 5, 40-46DOI: (10.1016/j.msard.2015.10.009) Copyright © 2015 The Authors Terms and Conditions
Fig. 2 FDO monitoring protocol used by RPHC (from Novartis product information). Multiple Sclerosis and Related Disorders 2016 5, 40-46DOI: (10.1016/j.msard.2015.10.009) Copyright © 2015 The Authors Terms and Conditions
Fig. 3 Mean HR (A) and BP (B) at each time point (n=850). Multiple Sclerosis and Related Disorders 2016 5, 40-46DOI: (10.1016/j.msard.2015.10.009) Copyright © 2015 The Authors Terms and Conditions
Fig. 4 Mean change in HR per patient from baseline at each time point (n=850). Multiple Sclerosis and Related Disorders 2016 5, 40-46DOI: (10.1016/j.msard.2015.10.009) Copyright © 2015 The Authors Terms and Conditions